United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
-- Investor breakfast event and webcast at ASGCT on Friday, May 12 at 7:00 a.m. EDT --
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferences taking place in May:
American Society of Gene and Cell Therapy (ASGCT), May 10 – 13 2017, at the Marriott Wardman Park hotel in Washington, D.C.
- Five abstracts have been accepted for presentation at the ASGCT meeting. Together with their collaborators, members of uniQure’s research and development team will present data focused on progress in re-administration protocols, gene therapy delivery systems and optimized vector distribution technologies in two of uniQure’s key programs, hemophilia-B and Huntington’s disease.
- In addition, uniQure management will host an investor and analyst breakfast meeting & webcast featuring senior leaders of its research and development team. To request attendance at the meeting, taking place at May 12, 2017 at 7:00 a.m. EDT, please RSVP to [email protected] by May 5, 2017, as space is limited.
- The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.
UBS Global Healthcare Conference, May 22 – 24 2017, at the Grand Hyatt New York, in New York City.
- Matthew Kapusta, chief executive officer, will present on Tuesday, May 23rd, 2017 at 3:00 p.m. EDT. The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.
American Biomanufacturing Summit, May 23 – 24 2017, at the Hyatt Regency Mission Bay Spa & Marina, in San Diego, California.
- Lance Weed, Vice President of US Operations, will be presenting: Developing a Scalable Disposable Manufacturing Facility for Producing Gene Therapies, on May 24 at 3:00 p.m. PT. uniQure's Lexington-based facility is one of the largest, most versatile gene therapy manufacturing facilities in the world, with state-of-the-art commercial-scale production capabilities that utilize 100% single-use components.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com.
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
